Novo Nordisk's Heart Disease Drug Fails in Clinical Trial, Stock Drops Over 10%
0xBroomberg
Novo Nordisk's experimental drug ziltivekimab failed to reduce heart attack and stroke risk in a large late-stage trial, sending shares down as much as 10.5% — a direct blow to the company's push beyond weight-loss drugs into cardiovascular medicine.
What does this drug actually target?
Ziltivekimab is an interleukin-6 inhibitor — a drug that blocks an inflammation-triggering protein in the immune system. It is injected once a month.
The target patient group: people with cardiovascular disease, chronic kidney disease, and inflammation at the same time. In plain terms = not a single-disease drug, but one aimed at the overlap of several chronic conditions.
Jefferies estimates this niche market is worth over $10 billion a year.
Why is this trial considered a failure?
The drug successfully lowered levels of its target protein in the body, but that biological effect did not translate into meaningful reduction in major cardiovascular events.
This means → the mechanism worked at the molecular level, yet patients' odds of heart attack and stroke did not improve. The science was right; the outcome didn't follow.
Jefferies had said the trial needed to show at least a 20% risk reduction to support broad clinical use. BMO Capital Markets set the bar at 15% with good safety. Neither threshold was met.
What does this mean for Novo Nordisk?
Ziltivekimab was seen as a key pillar of the company's second growth curve beyond GLP-1 weight-loss drugs. This reflects Novo's effort to reduce its dependence on a single franchise.
The first trial's failure hits that strategy directly. Two more ziltivekimab cardiovascular-outcome studies are still under way, but the market is cautious about whether they can reverse the picture.
Shares fell 10.5% intraday — the steepest one-day drop since February.
What does this mean for rival programs?
Novartis and Eli Lilly are both developing compounds that use the same mechanism — interleukin-6 inhibition.
This means → the trial failure is not Novo Nordisk's problem alone. It raises questions for the entire "anti-inflammatory approach to heart disease" thesis.
Put simply = if blocking the same protein does not cut heart-disease risk, competitors using the same playbook face the same question.
Content is for reference only, not financial advice.